Lilly Opens San Diego Gateway Labs to Support Early-Stage Biotech Companies

Eli Lilly has opened its newest Lilly Gateway Labs site in San Diego, California. The 82,514 sq. ft. facility, developed and operated in partnership with Alexandria Real Estate Equities, provides lab space and opportunities to collaborate with Lilly scientists for up to 15 early-stage biotechnology companies. This expansion supports the local biotechnology ecosystem and fuels next-generation medicines.

Eli Lilly and Company (NYSE: LLY) has announced the opening of its newest Lilly Gateway Labs (LGL) site in San Diego, California. The 82,514 square foot facility, developed and operated in partnership with Alexandria Real Estate Equities, Inc., will accommodate up to 15 early-stage biotechnology companies and support the local biotechnology ecosystem Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem^[1].

The new LGL San Diego site features flexible lab and office space designed to support the growth and collaboration of life sciences companies. The facility joins Lilly's existing Gateway Labs sites in South San Francisco and Boston, as well as the newly opened site in Beijing, further expanding the company's global innovation network Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem^[1].

"At Lilly, we are committed to meeting the biotech ecosystem on its own terms, supporting companies at every stage and evolving alongside them," said Daniel Skovronsky, M.D., Ph.D., chief scientific officer, and president, Lilly Research Laboratories and Lilly Immunology. "The future of medicine depends on combining the strengths of academia, biotech, and large pharma to solve some of the most difficult diseases facing patients. Our expanded presence here enables us to further connect with San Diego's vibrant startup community, world-leading scientists, and research institutions" Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem^[1].

Lilly Gateway Labs offers startups access to wet lab facilities along with tailored scientific engagement and strategic guidance to help navigate the complexities of drug discovery and development. The model is designed to accelerate progress towards key milestones by combining infrastructure with deep expertise Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem^[1].

Since the opening of the first Gateway Labs site in 2019, LGL-based companies have raised more than $2 billion in capital, supporting the development of 50+ therapeutics and platforms now in progress Lilly opens newest Gateway Labs site in San Diego to boost local biotechnology ecosystem^[1]. The companies based in Gateway Labs represent a diverse array of therapeutic approaches and disease areas, aligned with and outside of Lilly's core focus areas.

The weight loss drug market still has vast prospects, with most institutions predicting that the market size will reach the billion-dollar level by the end of this decade. Eli Lilly's weight loss drug Zepbound underperformed in sales in the third quarter, which has raised concerns among investors about the outlook of the weight loss drug market Eli Lilly and Co. is startled, novo-nordisk a/s saves the day! The market prospects for weight loss drugs still tempt many players.^[2].